SV2019005808A - Nuevos analógos de urocortina - 2 modificados con ácido graso para el tratamiento de diabetes y enfermedad renal cronica - Google Patents

Nuevos analógos de urocortina - 2 modificados con ácido graso para el tratamiento de diabetes y enfermedad renal cronica

Info

Publication number
SV2019005808A
SV2019005808A SV2019005808A SV2019005808A SV2019005808A SV 2019005808 A SV2019005808 A SV 2019005808A SV 2019005808 A SV2019005808 A SV 2019005808A SV 2019005808 A SV2019005808 A SV 2019005808A SV 2019005808 A SV2019005808 A SV 2019005808A
Authority
SV
El Salvador
Prior art keywords
etoxi
modified
fatty acid
amino
urocortine
Prior art date
Application number
SV2019005808A
Other languages
English (en)
Inventor
Fernandez Jorge Alsina
Lili Guo
John Lee
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SV2019005808A publication Critical patent/SV2019005808A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA UN COMPUESTO O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE FÓRMULA: X1 I V X2 S L D V P I G L L Q I L X3 E Q E K Q E K E K Q Q A K * T N A X4 I L A Q V-NH2, EN DONDE EL X1 INDICA QUE EL RESIDUO I ES MODIFICADO YA SEA POR ACETILACIÓN O METILACIÓN EN EL EXTREMO N-TERMINAL; EN DONDE X2 ES L O T; EN DONDE X3 ES L O I; EN DONDE X4 ES Q O E; Y EN DONDE UN RESIDUO K MODIFICADO (¿K*¿) EN LA POSICIÓN 29 ES MODIFICADO A TRAVÉS DE LA CONJUGACIÓN AL GRUPO EPSILÓN ¿ AMINO DE LA CADENA LATERAL K CON UN GRUPO DE LA FÓRMULA ¿X5-X6, EN DONDE X5 SE SELECCIONA DEL GRUPO QUE CONSISTE DE UNO A CUATRO AMINOÁCIDOS; UNA A CUATRO PORCIONES DE ( [2 ¿ (2-AMINO-ETOXI) - ETOXI] ¿ ACETIL); Y COMBINACIONES DE UNO A CUATRO AMINOÁCIDOS Y UNA A CUATRO PORCIONES DE ( [2 ¿ (2-AMINO-ETOXI) ¿ ETOXI] ¿ ACETIL); Y X6 ES UNA ÁCIDO GRASO DE C14-C24. EN ALGUNAS MODALIDADES, EL GRUPO DE LA FÓRMULA ¿X5-X6 ES ( [2 ¿ (2-AMINO-ETOXI) ¿ ETOXI] ¿ ACETIL) 2- (YE)2 ¿ CO ¿ (CH2)X ¿ CO2H DONDE X ES 16 O 18
SV2019005808A 2016-07-15 2019-01-11 Nuevos analógos de urocortina - 2 modificados con ácido graso para el tratamiento de diabetes y enfermedad renal cronica SV2019005808A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662362711P 2016-07-15 2016-07-15
US201662431682P 2016-12-08 2016-12-08
US201762491385P 2017-04-28 2017-04-28

Publications (1)

Publication Number Publication Date
SV2019005808A true SV2019005808A (es) 2019-04-04

Family

ID=59501524

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2019005808A SV2019005808A (es) 2016-07-15 2019-01-11 Nuevos analógos de urocortina - 2 modificados con ácido graso para el tratamiento de diabetes y enfermedad renal cronica

Country Status (24)

Country Link
US (1) US10894817B2 (es)
EP (1) EP3484495B1 (es)
JP (1) JP2019525919A (es)
KR (1) KR20190017982A (es)
CN (1) CN109475592B (es)
AU (1) AU2017295708B2 (es)
BR (1) BR112018076693A2 (es)
CA (1) CA3030965C (es)
CL (1) CL2019000043A1 (es)
CO (1) CO2018014026A2 (es)
CR (1) CR20190015A (es)
DO (1) DOP2019000007A (es)
EC (1) ECSP19003047A (es)
ES (1) ES2901477T3 (es)
IL (1) IL264025A (es)
JO (1) JOP20170153A1 (es)
MA (1) MA45673A (es)
MX (1) MX2019000661A (es)
PE (1) PE20190470A1 (es)
PH (1) PH12019500074A1 (es)
SG (1) SG11201811737SA (es)
SV (1) SV2019005808A (es)
TW (1) TW201811821A (es)
WO (1) WO2018013803A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
PT3436461T (pt) 2016-03-28 2024-01-23 Incyte Corp Compostos de pirrolotriazina como inibidores de tam
JP2020535168A (ja) 2017-09-27 2020-12-03 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｔａｍ阻害剤として有用なピロロトリアジン誘導体の塩
WO2019140030A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
WO2019140021A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
WO2019140025A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
WO2019140024A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
WO2019140023A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
TWI832871B (zh) 2018-06-29 2024-02-21 美商英塞特公司 Axl/mer 抑制劑之調配物
US20200027555A1 (en) * 2018-07-17 2020-01-23 Lewis Pharmaceutical Information, Inc. Patient centric drug analysis platform
IL300464A (en) 2020-08-19 2023-04-01 Sanofi Sa CRF2 receptor agonists and their use in therapy
MX2023008330A (es) 2021-01-20 2024-01-18 Viking Therapeutics Inc Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos.
WO2023285347A1 (en) * 2021-07-12 2023-01-19 Novo Nordisk A/S Novel fatty acid modified urocortin 2 derivatives and the uses thereof
EP4234574A1 (en) 2022-02-23 2023-08-30 Corteria Pharmaceuticals Crf2 receptor agonists and their use in therapy

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0724637B2 (en) 1994-06-14 2002-06-05 Neurocrine Biosciences, Inc. Corticotropin-releasing factor 2 receptors
AU6277796A (en) * 1995-06-13 1997-01-15 Salk Institute For Biological Studies, The Urocortin peptides
US20040034882A1 (en) 1999-07-15 2004-02-19 Vale Wylie W. Corticotropin releasing factor receptor 2 deficient mice and uses thereof
WO2002012307A1 (en) * 2000-08-04 2002-02-14 Research Development Foundation Urocortin proteins and uses thereof
US20020082409A1 (en) 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
CA2425902C (en) 2001-03-15 2017-01-03 Research Development Foundation Urocortin-iii and uses thereof
US6936585B2 (en) * 2002-01-16 2005-08-30 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
GR1004664B (en) 2002-11-26 2004-09-02 Bionature E A Ltd The charakteristics and advantages of our invention are illustrated by the following description, methods and results of our research, attached figures and supporting references
WO2005103690A2 (en) 2004-04-24 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with corticotropin releasing hormone receptor 2 (crhr2)
WO2006031322A2 (en) 2004-08-09 2006-03-23 Research Development Foundation Determination of the 3d-structure of an extracellular domain of a b1 g-protein coupled receptor by nmr analysis
US7507794B2 (en) 2005-02-08 2009-03-24 Research Development Foundation Isolated soluble corticotropin releasing factor receptor type 2 (sCRFR2)
US7815905B2 (en) 2006-01-27 2010-10-19 Research Development Foundation Methods of increasing insulin sensitivity or decreasing insulin secretion by administering corticotropin releasing factor receptor-2 inhibitors
WO2008047241A2 (en) * 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
CA2692039C (en) 2007-06-13 2019-07-02 Research Development Foundation Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating crf receptor signaling
US10040838B2 (en) 2008-11-04 2018-08-07 Janssen Pharmaceutica Nv CRHR2 peptide agonists and uses thereof
ES2545794T3 (es) * 2009-08-28 2015-09-15 Research Development Foundation Análogos de urocortina 2 y usos de los mismos
JP2013510167A (ja) 2009-11-04 2013-03-21 ヤンセン ファーマシューティカ エヌ．ベー． ストレスコピン様ペプチドによる心不全の治療方法
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
WO2011095450A1 (en) 2010-02-02 2011-08-11 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
WO2013063046A1 (en) 2011-10-24 2013-05-02 Research Development Foundation Methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors
US20160166651A1 (en) 2014-04-03 2016-06-16 The Regents Of The University Of California Systemic delivery of virus vectors encoding urocortin-2 and related genes to treat diabetes-related cardiac dysfunctions and congestive heart failure
TWI783244B (zh) * 2015-06-22 2022-11-11 美商美國禮來大藥廠 升糖素及glp-1共激動劑化合物
WO2017220706A1 (en) * 2016-06-22 2017-12-28 Novo Nordisk A/S Pharmaceutical compositions of fgf21 derivatives and uses thereof

Also Published As

Publication number Publication date
ES2901477T3 (es) 2022-03-22
CA3030965A1 (en) 2018-01-18
JP2019525919A (ja) 2019-09-12
PE20190470A1 (es) 2019-04-04
CN109475592B (zh) 2022-08-09
KR20190017982A (ko) 2019-02-20
JOP20170153A1 (ar) 2019-01-30
US10894817B2 (en) 2021-01-19
EP3484495B1 (en) 2021-09-08
TW201811821A (zh) 2018-04-01
MA45673A (fr) 2021-05-26
CR20190015A (es) 2019-02-27
EP3484495A1 (en) 2019-05-22
ECSP19003047A (es) 2019-01-31
PH12019500074A1 (en) 2019-07-29
AU2017295708B2 (en) 2019-05-09
CO2018014026A2 (es) 2019-01-18
DOP2019000007A (es) 2019-04-15
CA3030965C (en) 2022-04-26
BR112018076693A2 (pt) 2019-04-02
AU2017295708A1 (en) 2018-12-20
SG11201811737SA (en) 2019-01-30
CL2019000043A1 (es) 2019-06-07
MX2019000661A (es) 2019-05-15
US20180016318A1 (en) 2018-01-18
WO2018013803A1 (en) 2018-01-18
IL264025A (en) 2019-01-31
CN109475592A (zh) 2019-03-15

Similar Documents

Publication Publication Date Title
SV2019005808A (es) Nuevos analógos de urocortina - 2 modificados con ácido graso para el tratamiento de diabetes y enfermedad renal cronica
ES2606173T3 (es) Composición farmacéutica para el tratamiento y/o la prevención del cáncer
CL2020002026A1 (es) Inhibidor de fap.
HRP20191614T1 (hr) Spojevi koji su suagonisti gip i glp-1
PE20120586A1 (es) Proteinas de union a il-1
PE20141672A1 (es) FORMULACION PARA ANTICUERPO ANTI-alfa4�7
AR067555A1 (es) Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal
UY30339A1 (es) Acidos carboxilicos sustituidos con 4,5-difenilpirimidinilamino, procedimientos para su preparacion y su uso como productos farmacéuticos
AR070276A1 (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2 y sus variantes acidas. formulacion farmaceutica. usos. metodo de preparacion.
CL2009001340A1 (es) Compuesto de insulina lispro pegilada o una sal del mismo que comprende una cadena a de sec no:1, una cadena b de sec no:3 y el peg es de un peso entre 20 a 40 kda; uso de dicho compuesto para tratar hipoglicemia o diabetes; composición farmacéutica que comprende dicho compuesto; y proceso para elaborar dicho compuesto.
CL2013000716A1 (es) Un profarmaco o una sal del mismo que comprende un conjugado de exendina-conector; procedimiento de preparacion de dicho profarmaco; compuestos intermediarios; composicion farmaceutica que lo comprende, util para mejorar el control glucemico en pacientes con diabetes de tipo 2.
UY30337A1 (es) Acidos carboxilicos sustituidos con 4,5-difenilpirimidinilo, procedimientos para su preparacion y su uso como productos farmacéuticos.
CL2017003097A1 (es) Composiciones y métodos para el tratamiento de la enfermedad celiaca
PE20120204A1 (es) Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas
EA201591391A1 (ru) Производное 2-ациламинотиазола или его соль
CO6592101A2 (es) Metodos para tratar ulceras de pie de diabetico
PE20171622A1 (es) Formulacion de relacion fija de insulina glargina/lixisenatida
EA201491513A1 (ru) Рекомбинантные штаммы escherichia coli
CL2019001746A1 (es) Amidas aromáticas de ácido carboxílico
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
EA201790223A1 (ru) Водный препарат, содержащий парацетамол и ибупрофен
ES2673406T3 (es) Alfa-derivados de ácidos grasos cis-monoinsaturados para uso como medicamentos en el tratamiento de la diabetes
AR079170A1 (es) Compuesto de ciclopropil-benzamida-imidazo-benzazepina inhibidor de diacil-glicerol aciltransferasa, sal del mismo, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de obesidad o para mejorar la sensibilidad a insulina y compuesto intermedio par
UY33568A (es) Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes.
AR075041A1 (es) Composicion farmaceutica que contiene aleglitazar, proceso, uso.